Hematologic markers of distant metastases in gastric cancer

Gastric cancer is the second most common gastrointestinal malignancy after colorectal cancer (CRC) with one million cases diagnosed worldwide annually (1). Around 40% of gastric cancer patients have distant metastases at the time of diagnosis (2). Despite the recent advancements in the management of metastatic gastric cancer, the prognosis remains poor with a 5-year survival rate of less than 4% (3)